文献速递造血干细胞移植与细胞治疗

BMT-CARE应用程序:针对造血干细胞移植患者照护者的心理社会数字应用随机对照试验

BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation.
PubMed 文献 · J Clin Oncol · 2025-05-30

该随机对照试验纳入125名接受造血干细胞移植的血液恶性肿瘤成人照护者,比较BMT-CARE数字心理社会应用与常规照护。移植后第60天,BMT-CARE组照护者生活质量显著优于常规照护组(校正均值76.3 vs 69.9,P=0.006),照护负担、抑郁和创伤后应激障碍症状也显著更低,焦虑症状两组无显著差异。

要点

  • BMT-CARE应用可显著改善移植照护者第60天生活质量(校正均值76.3 vs 69.9,P=0.006)
  • 照护负担(11.2 vs 12.3,P=0.023)、抑郁(3.8 vs 5.6,P=0.002)和PTSD症状(26.1 vs 31.3,P=0.012)均显著更低
  • 焦虑症状两组无显著差异;作者建议在多中心研究中验证

核心结论

  • BMT-CARE应用显著改善了造血干细胞移植照护者的生活质量、照护负担、抑郁和创伤后应激障碍症状。
  • 作者建议在多中心研究及多样化造血干细胞移植照护者人群中检验该干预以确定其可推广性和可扩展性。

研究设计与样本

  • 随机对照试验,比较心理社会数字应用BMT-CARE与常规照护。
  • 纳入接受造血干细胞移植的血液恶性肿瘤成人照护者,2023年2月至2024年7月共入组125/174名被接触照护者(71.8%)。
  • BMT-CARE应用包含五个模块,结合心理教育与循证行为改变策略。
  • 参与者在基线和移植后第60天完成自评量表,主要终点为第60天采用CareGiver Oncology QOL(CarGOQOL)评估的生活质量。
  • 采用协方差分析校正基线评分评估干预效果。

主要发现

  • BMT-CARE组应用使用时间中位数为146.9分钟(范围0-384.8)。
  • 第60天BMT-CARE组照护者生活质量临床且显著优于常规照护组(校正均值76.3 vs 69.9,P=0.006)。
  • BMT-CARE组照护负担显著更低(11.2 vs 12.3,P=0.023)。
  • BMT-CARE组抑郁症状显著更低(3.8 vs 5.6,P=0.002)。
  • BMT-CARE组创伤后应激障碍症状显著更低(26.1 vs 31.3,P=0.012);第60天焦虑症状两组无显著差异。

关键数值与推荐

  • 主要终点第60天生活质量采用CarGOQOL评估,BMT-CARE组校正均值76.3 vs 常规照护组69.9(P=0.006)。
  • 照护负担采用Caregiver Reaction Assessment评估,BMT-CARE组11.2 vs 常规照护组12.3(P=0.023)。
  • 抑郁症状采用医院焦虑抑郁量表评估,BMT-CARE组3.8 vs 常规照护组5.6(P=0.002)。
  • 创伤后应激障碍症状采用PTSD Checklist(PCL-5)评估,BMT-CARE组26.1 vs 常规照护组31.3(P=0.012)。
  • 焦虑症状第60天两组无显著差异。

临床怎么用

  • 作者建议该干预应在多中心研究及多样化造血干细胞移植照护者人群中检验,以确定可推广性和可扩展性。

局限性

  • 作者建议在多中心研究及多样化造血干细胞移植照护者人群中检验该干预以确定可推广性和可扩展性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Family and friend caregivers of patients undergoing hematopoietic stem-cell transplantation (HSCT) struggle with immense caregiving burden, leading to substantial quality of life (QOL) impairments and psychological distress. Yet, interventions to address caregivers' needs are limited. MATERIALS AND METHODS: We conducted a randomized controlled trial of a psychosocial digital application (BMT-CARE App) versus usual care for adult caregivers of patients with hematologic malignancies undergoing HSCT. The BMT-CARE App included five modules combining psychoeducation and evidence-based behavior change strategies. Participants completed self-report measures at baseline and day 60 post-HSCT. The primary end point was QOL at day 60 assessed by the CareGiver Oncology QOL (CarGOQOL) measure. We also assessed caregiving burden (Caregiver Reaction Assessment), anxiety and depression symptoms (Hospital Anxiety and Depression Scale), and post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist [PCL-5]). We used analysis of covariance adjusting for baseline scores to assess the effect of the intervention on study outcomes. RESULTS: Between February 2023 and July 2024, we enrolled 125 of 174 approached caregivers (71.8%). Participants assigned to the BMT-CARE App used the app for a median of 146.9 minutes (range, 0-384.8). At day 60, BMT-CARE App caregivers reported clinically and significantly better QOL than those assigned to usual care (adjusted means = 76.3 v 69.9, P = .006). BMT-CARE App participants also reported significantly lower caregiving burden (11.2 v 12.3, P = .023), depression (3.8 v 5.6, P = .002), and PTSD symptoms (26.1 v 31.3, P = .012). The groups did not differ significantly in anxiety symptoms at day 60. CONCLUSION: The BMT-CARE App led to significantly improved QOL, caregiving burden, depression, and PTSD symptoms among HSCT caregivers. This intervention should be tested in a multicenter study with a diverse HSCT caregiver population to determine generalizability and scalability.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Jacobs JM, Traeger L, Freese M, et al. BMT-CARE App: A Randomized Controlled Trial of a Psychosocial Digital Application for Caregivers of Patients Undergoing Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2025. PMID: 40444925. doi:10.1200/JCO-25-00713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。